Détails du produit
Synonyms
LY6E, Ly-6E, Ly6E, RIG-E, SCA-2, TSA-1, 9804, RIGE, SCA2, TSA1
Source
Human Ly6E Protein, Fc Tag (LYE-H5253) is expressed from human 293 cells (HEK293). It contains AA Leu 21 - Ser 101 (Accession # Q16553-1).
Predicted N-terminus: Leu 21
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 34.9 kDa. The protein migrates as 40-43 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE

Human Ly6E Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA

Immobilized Human Ly6E Protein, Fc Tag (Cat. No. LYE-H5253) at 1 μg/mL (100 μL/well) can bind Anti-LY6E (RG7841 biosimilar) mAb, Human IgG1 with a linear range of 1-16 ng/mL (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire

Introduction de fond
Progrès de frontière
- Nom anglais:
Lymphocyte antigen 6E
- Catégorie:
- Nombre de médicaments répertoriés:
0 Détails
- Nombre de médicaments cliniques:
1 Détails
- Étape de développement la plus élevée:
Phase 1 Clinical



















